StockpollyBeta
Get App
Popularity #3,217
FHTX · NASDAQ · Biotechnology

Foghorn Therapeutics (FHTX)

Develops oncology drugs from a Gene Traffic Control discovery platform.

$4.06
vs last close−0.18 (−4.25%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue17657836889316
Cost of revenue26100000120100
Gross profit−95578367−128316
8303334322729287282525
Research & development262326242521222120231819
878776777776
General & administrative878776777776
Other expenses−260020000−20−200
Operating income−17−25−28−27−24−24−23−21−19−20−22−9
333455433−222
Interest income332333322222
Other non-operating income0−3−3−2−5−5−4−3−32−2−2
Income before tax−14−22−25−23−19−20−19−18−16−22−20−7
Income tax expense120000000000
Net income from continuing operations−14−24−25−23−19−20−19−18−16−22−20−7
Net income−14−24−25−23−19−20−19−18−16−22−20−7
EPS, basic−$0.34−$0.57−$0.59−$0.45−$0.31−$0.31−$0.30−$0.28−$0.25−$0.35−$0.29−$0.10
EPS, diluted−$0.34−$0.57−$0.59−$0.45−$0.31−$0.31−$0.30−$0.28−$0.25−$0.35−$0.29−$0.10
Weighted average shares, basic424242526363636363637071
Weighted average shares, diluted424242526363636363637071
EBITDA−16−21−24−23−18−19−18−17−15−21−20−7
Depreciation & amortization111111111100
EBIT−17−22−25−24−19−20−19−18−16−22−20−7